Although PD-L1 expression is predictive of the response to PD-L1/PD-1 inhibitors in patients with lung cancer and melanoma, this association was not established in patients with ccRCC in the CheckMate 025 trial [1, 11, 12]. Here, CD274 is linked to lung carcinoma.